CARACO PHARMACEUTICAL LABORATORIES LTD Form 8-K August 25, 2005 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 19, 2005 (Date of report) CARACO PHARMACEUTICAL LABORATORIES, LTD. (Exact name of registrant as specified in its charter) Michigan 0-24676 38-2505723 (State or other jurisdiction of (Commission file number) (I.R.S. employer identification no.) incorporation) 1150 Elijah McCoy Drive, Detroit, Michigan 48202 (Address of principal executive offices) (313) 871-8400

(Registrant s telephone number, including area code)

<u>Nc</u>	t Applicable
(Fo	ormer name or former address, if changed since last report)
	eck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of following provisions:
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement.

On August 19, 2005, the Compensation Committee of the Board of Directors of registrant approved annual salaries (for fiscal year 2006, effective April 1, 2005) and eligibility for performance bonuses based on achievement of various criteria during fiscal year 2006 to its executive officers (other than the Chief Executive Officer) as follows:

Name	<u>Title</u>	Fiscal 2006	Fiscal 2006
		Salary	Performance Bonus Eligibility
Jitendra N. Doshi	CFO & COO	\$200,000	up to 30% of salary
Robert Kurkiewicz	Sr. V.P Technical	\$152,250	up to 23% of salary
Gurpartap Singh	V.P. Sales &	\$175,500	up to 25% of salary
Sachdeva	Marketing		

Item 9.01. Financial Statements and Exhibits

c) Exhibits.

Exhibit No. Description

10.16 Summary of fiscal year 2006 executive officer salaries and performance bonus eligibility (other than the Chief Executive Officer).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARACO PHARMACEUTICAL LABORATORIES, LTD.

Date: August 25, 2005 By: /s/ Daniel H. Movens

Daniel H. Movens

Chief Executive Officer

Exhibit Index

10.16 Summary of fiscal year 2006 executive officer salaries and performance bonus eligibility (other than the Chief Executive Officer).

_